Stage II human trials have Indicated that the combination of 3'-azido-3'-deoxythymidine (AZT) with 5-fluorouracil and leucovorin has ~mproved efficacy in the adjuvant chemotherapy of colorectal cancer. The development of resistance to AZT has been well documented in viral metabolism, but has not been fully described in human cells. This renders the drug clinically unpredictable, limiting its chemotherapeutic utility. In order to better study the mechanism of AZT-resistance, we have developed an AZT-resistant colon cancer cell line i n culture to serve as a model system.
The human colon adenocarcinoma cell line, HCT-15 (American Type Culture Collection #CCL225), has been previously characterized by convent~onal cytogenetlc studies and by fluorescent in silu hybridization (FISH). We have measured the concentration of AZT necessary to inhibit growth by 50% over 5 days (ICso) to be approximately 30 pM AZT-resistant cell lines were derived by serial passage of HCT-15 cells i n ~ncreasing concentrations of AZT until stable growth was achieved in 1000 pM AZT. The surviving cell colonies were then subcloned in soft agar. One such cell line, clone 5, was found to have eighty-fold Increased resistance to AZT, with an ICg of approximately 2500 pM AZT. We now report a preliminary characterization of the clone 5 cell line in comparison to its parent HCT-15 cell line, using conventional G-banding techniques.
Epilepsy, genetics, neurotransmitter a m i n o acids a n d anticonvulsants. N.A. laniual, T. 1tanok M. ~n d o 2 , a n d S. o n i s h i 2 Departments of l~i o l o~~ a n d 2~ediatrics, Faculty of Medicine, Kagawa Medical University, Kagawa, Japan.
O n e approach to study t h e genetic a n d biochemical m e c h a n i s m s of epilepsy is t o undertake family studies involving investigation of candidate biochemical pathways. Using this approach, familial changes i n plasma levels of glutamic acid, aspartic acid a n d t a u r i n e h a v e b e e n observed and a genetic basis for these changes h a s b e e n proposed. However, almost all of these studies h a v e i n v o l v e d patients receiving anticonvulsants thereby raising t h e possibility that t h e observed changes could be medication related. T o clarify t h e possible effect of anticonvulsants on neurotransmitter a m i n o acids, w e examined plasma levels of these a m i n o acids i n patients w i t h a n d w i t h o u t anticonvulsant therapy. T h e study group comprised 31 primary generalized epilepsy patients including 24 with a n d 7 w i t h o u t anticonvulsant treatment. T h e latter were patients w h o w e r e investigated either prior to therapy o r were n o t receiving anticonvulsants as they had been seizure free. Amino acid analyses were d o n e o n fasting blood samples using a n automatic a m i n o acid analyzer. Results s h o w e d n o significant differences i n plasma levels of glutarnic acid, aspartic acid a n d t a u r i n e between patients with a n d without therapy. T h e s e findings suggest that plasma neurotransmitter a m i n o acids i n epileptic patients may n o t be altered by anticonvulsants a n d p r o v i d e further support to t h e hypothesis that familial changes i n plasma glutamic acid, aspartic acid a n d taurine i n epilepsy h a v e a genetic basis. Anomaly scan on a 21 year old pnmigravida at 22 weeks showed absence of the superior portion of the calvarium with poorly defined cerebral tissue floating in the amniotic fluid. Maternal serum alphafetoprotein (MSAFP) at 18 weeks was I .4 MOM. The patient was counseled for anencephaly and amniocentesis was performed. Biochemical data consisting of amniotic fluid alphafetoprotein (AFAFP) of 1.94 MOM with weak positive acetylcholinesterase (ACHE) was atypical of classic anencephaly; karyotype was 46,XX. Following termination. fetopsy showed a gaping cranial defect with protruding brain tissue, partially covered by attenuated translucent skin; meninges were tom and congested. Amniotic bands were identified explaining the cranial findings.
Radial aplasia and imperforate anus further suggested VATER. While normal MSAFP can be seen with anencephaly, a normal AFAFP and weak positive ACHE are atypical. In the context of the post-mortem findings. it is presumed that without pregnancy termination, expansion of the cranial anomaly would have eventually lead to unequivocally abnormal biochemical results. This case suggests that alternative etiologies, in particular amniotic bands, be considered when atypical biochemical data is seen at midtrimester in the presence of apparent anencephaly.
In many X-linked and autosomal disorders. the absence of a mutation in the parents of an Isolated affected child with a known mutatlon 1s still compatible with a significant recurrence risk because of parental mosaicism. Mosaicism has always been a theoretical possibility in Lowe Syndrome but has not been demonstrated to date. Proband LS-54, an isolated patient with Lowe syndrome, is hernizygous for a C 3 T transition in exon 18 which converts arginine to a stop at position 678 of the OCRLl gene. The mutation is readily detectable because it creates an additional DdeI site within exon 18. Analysis of his mother's DNA obtained from peripheral blood leukocytes (PBL) revealed no mutatlon. Surpr~singly, however, slit lamp examination of her lens by two independent observers revealed numerous micropunctate opacities distr~buted in a pattern characteristic of the carrier state for Lowe syndrome. Mutation analysis repeated on fresh samples of PBL DNA from the proband and his mother as well as on buccal scraping (BS) DNA from his mother confirmed the R678X mutation in the proband and its absence in DNA from both PBL and BS DNA in his mother. We interpret these results as indicating the mother is a likely somatic and germline mosaic for the mutation. Genetic counseling for Lowe Syndrome must take mosaicism into account when a DNA sample from the mother of an isolated case fails to demonstrate the mutation seen in an affected child.
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